Advertisement

Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis

  • Author Footnotes
    1 Xiang Li and Min Wang contributed equally to this work and should be considered co-first authors.
    Xiang Li
    Correspondence
    Corresponding author. Tel.: +86 10 66867401.
    Footnotes
    1 Xiang Li and Min Wang contributed equally to this work and should be considered co-first authors.
    Affiliations
    Department of Pharmacy, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
    Search for articles by this author
  • Author Footnotes
    1 Xiang Li and Min Wang contributed equally to this work and should be considered co-first authors.
    Min Wang
    Footnotes
    1 Xiang Li and Min Wang contributed equally to this work and should be considered co-first authors.
    Affiliations
    Medical Department, No. 263 Clinical Department, Beijing Military General Hospital, Beijing 101149, China
    Search for articles by this author
  • Guiyang Liu
    Affiliations
    Department of Pharmacy, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
    Search for articles by this author
  • Jianli Ma
    Affiliations
    Department of Pharmacy, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
    Search for articles by this author
  • Chuntong Li
    Affiliations
    Department of Pharmacy, First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, China
    Search for articles by this author
  • Author Footnotes
    1 Xiang Li and Min Wang contributed equally to this work and should be considered co-first authors.
Published:September 24, 2015DOI:https://doi.org/10.1016/j.ejim.2015.09.009

      Abstract

      Background

      A large body of evidences suggested that macrolide therapy could improve the survival of patients with various infections. While in the same time, macrolides are known to increase fatal arrhythmogenic risks and cause cardiac death. To assess the risks and benefits of macrolide therapy, we systematically reviewed all studies of macrolide use, cardiac death and mortality among patients with various infections.

      Methods

      We searched Pubmed, Embase and Cochrane library and reviewed reference lists from 1980 through April 2015. Studies were included if they compared macrolides to other antibiotics in adults with various infections. The outcome measures were the overall mortality and the risk of cardiac death.

      Results

      Overall, macrolide use was associated with a statistically significant mortality reduction compared with nonmacrolide use (OR: 0.65, 95% CI: 0.46–0.92). There was no difference in the risk of cardiac death between macrolide and nonmacrolide regimes (OR: 1.43, 95% CI: 0.86–2.40). In subgroup analyses, macrolide use was found to be associated with the decreased risk of mortality in a population of older individuals (age > 48 years, OR: 0.69; 95% CI: 0.66–0.72). While in a general population of young and middle-aged adults, the use of macrolide-based regimens could not decrease the risk of death from any cause (age < 48 years, OR: 0.42; 95% CI: 0.02–11.01). As for cardiac death, macrolide use was found to be associated with increased risk of cardiac death in a population of older individuals (age > 48 years, OR: 1.99; 95% CI: 1.53–2.59).

      Conclusion

      Despite the potential cardiotoxic effects, there is a net benefit associated with macrolide use in older patients with various infections and macrolide use except roxithromycin was found to be associated with increased risk of cardiac death in a population of adults aged > 48 years.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Sperryville VA. Antimicrobial therapy. Sanford guide to antimicrobial therapy. 43th edn. Antimicrobial Therapy Poc Press; 2013.

        • Bril F.
        • Gonzalez C.D.
        • Girolamo G.D.
        Antimicrobial agents-associated with QT interval prolongation.
        Curr Drug Saf. 2010; 5: 85-92
      2. FDA Drug Safety Communication. Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms; 2013. Database: figshare [Internet]. Accessed :http://www.fda.gov/drugs/drugsafety/ucm341822.html.

        • Gleason P.P.
        • Meehan T.P.
        • Fine J.M.
        • Galusha D.H.
        • Fine M.J.
        Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
        Arch Intern Med. 1999; 159: 2562-2572
        • Frei C.R.
        • Restrepo M.I.
        • Mortensen E.M.
        • Burgess D.S.
        Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
        Am J Med. 2006; 119: 865-871
        • Mortensen E.M.
        • Halm E.A.
        • Pugh M.J.
        • Copeland L.A.
        • Metersky M.
        • Fine M.J.
        • et al.
        Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.
        JAMA. 2014; 311: 2199-2208
        • Ray W.A.
        • Murray K.T.
        • Hall K.
        • Arbogast P.G.
        • Stein C.M.
        Azithromycin and the risk of cardiovascular death.
        N Engl J Med. 2012; 366: 1881-1890
      3. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort, studies. BMJ.2013; 346: f1235.

        • Svanström H.
        • Pasternak B.
        • Hviid A.
        Use of azithromycin and death from cardiovascular causes.
        N Engl J Med. 2013; 368: 1704-1712
      4. Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ.2014; 349: g4930.

        • Arnold F.W.
        • LaJoie A.S.
        • Brock G.N.
        • Peyrani P.
        • Rello J.
        • Menendez R.
        • et al.
        Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
        Arch Intern Med. 2009; 169: 1515-1524
        • Asadi L.
        • Eurich D.T.
        • Gamble J.M.
        • Minhas-Sandhu J.K.
        • Marrie T.J.
        • Majumdar S.R.
        Guideline adherence and macrolides reduced mortality in outpatients with pneumonia.
        Respir Med. 2012; 106: 451-458
        • Brown R.B.
        • Iannini P.
        • Gross P.
        • Kunkel M.
        Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
        Chest. 2003; 123: 1503-1511
        • Frei C.R.
        • Restrepo M.I.
        • Mortensen E.M.
        • Burgess D.S.
        Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
        Am J Med. 2006; 119: 865-871
        • Rao G.A.
        • Mann J.R.
        • Shoaibi A.
        • Bennett C.L.
        • Nahhas G.
        • Sutton S.
        • et al.
        Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.
        Ann. Fam. Med. 2014; 12: 121-127
        • Hancox J.C.
        • Hasnain M.
        • Vieweg W.V.
        • Crouse E.L.
        • Baranchuk A.
        Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports.
        Ther Adv Infect Dis. 2013; 1: 155-165
        • Howard P.A.
        Azithromycin-induced proarrhythmia and cardiovascular death.
        Ann Pharmacother. 2013; 47: 1547-1551
        • Garcia-Vidal C.
        • Fernández-Sabé N.
        • Carratalà J.
        • Díaz V.
        • Verdaguer R.
        • Dorca J.
        • et al.
        Early mortality in patients with community-acquired pneumonia: causes and risk factors.
        Eur. Respir. J. 2008; 32: 733-739
        • Paganin F.
        • Lilienthal F.
        • Bourdin A.
        • Lugagne N.
        • Tixier F.
        • Génin R.
        • et al.
        Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor.
        Eur. Respir. J. 2004; 24: 779-785
        • Restrepo M.I.
        • Mortensen E.M.
        • Waterer G.W.
        • Wunderink R.G.
        • Coalson J.J.
        • Anzueto A.
        Impact of macrolides therapy on mortality for patients with severe sepsis due to pneumonia.
        Eur Respir J. 2009; 33: 153-159
        • Restrepo M.
        • Mortensen E.
        • Copeland L.
        • Nakashima B.
        • Pugh M.
        • Anzueto A.
        Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis.
        Eur. Respir. J. 2011; 38: 2554
        • Rodriguez A.
        • Mendia A.
        • Sirvent J.M.
        • Barcenilla F.
        • de la Torre-Prados M.V.
        • Sole-Violan J.
        • et al.
        Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock.
        Crit Care Med. 2007; 35: 1493-1498
        • Zarogoulidis P.
        • Papanas N.
        • Kioumis I.
        • Chatzaki E.
        • Maltezos E.
        • Zarogoulidis K.
        Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.
        Eur J ClinPharmacol. 2012; 68: 479-503
        • Amsden G.W.
        Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?.
        J. Antimicrob. Chemother. 2005; 55: 10-21
        • Spagnolo P.
        • Fabbri L.M.
        • Bush A.
        Long-term macrolide treatment for chronic respiratory disease.
        Eur. Respir. J. 2013; 42: 239-251
        • Healy D.P.
        Macrolide immunomodulation of chronic respiratory diseases.
        Curr Infect Dis Rep. 2007; 9: 7-13